Related Experiment Video

Updated: Aug 15, 2026

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

Link between heart disease, cholesterol, and Alzheimer's disease: a review

D L Sparks1, T A Martin, D R Gross

  • 1Haldeman Laboratory for Alzheimer's Disease Research, Sun Health Research Institute, Sun City, Arizona, USA. Lsparks@mail.sunhealth.org

Microscopy Research and Technique
|August 11, 2000
PubMed

Insights

Heart disease is linked to Alzheimer's disease-like beta-amyloid buildup in the brain. Lowering cholesterol, potentially with HMG-CoA reductase inhibitors, may reduce this harmful protein accumulation.

Area of Science:

  • Neuroscience
  • Cardiovascular Science
  • Biochemistry

Background:

  • Heart disease is frequently observed in Alzheimer's disease (AD) patients and may precede cognitive decline.
  • Alzheimer's disease is characterized by beta-amyloid (Aβ) deposits in the brain.
  • Individuals with heart disease can exhibit increased Aβ deposition, even without dementia.

Purpose of the Study:

  • To investigate the relationship between cholesterol, heart disease, and beta-amyloid production.
  • To explore the potential of cholesterol reduction therapies for mitigating Aβ accumulation.

Main Methods:

  • Utilized a cholesterol-fed rabbit model mimicking human coronary heart disease.
  • Examined beta-amyloid production in cultured cells challenged with cholesterol.
  • Assessed the impact of HMG-CoA reductase inhibitors on beta-amyloid levels in animal models.

Main Results:

  • Dietary cholesterol induced beta-amyloid production and accumulation in rabbit brains.
  • Cholesterol reduction reversed brain beta-amyloid accumulation in rabbits.
  • Cholesterol challenge increased beta-amyloid production in cell cultures.
  • HMG-CoA reductase inhibitors significantly reduced cholesterol-induced beta-amyloid production.

Conclusions:

  • Dietary cholesterol and associated heart disease contribute to beta-amyloid accumulation in the brain.
  • Reducing cholesterol levels, potentially via HMG-CoA reductase inhibitors, may be a viable strategy to decrease beta-amyloid production.
  • Further research and clinical trials are warranted to explore HMG-CoA reductase inhibitors for Alzheimer's disease treatment.

More Related Videos

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment08:43

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment

Published on: August 7, 2017

Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol10:12

Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol

Published on: March 25, 2020

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...